Oklahoma Medical Research Foundation | Oklahoma City, OK
Status and phase
Conditions
Treatments
About
The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response after 52 weeks of treatment in patients with active lupus nephritis (LN).
Full description
This study aims to investigate whether zetomipzomib, added to standard of care treatment in patients with active LN, is able to reduce disease activity over a treatment period of 52 weeks. The background standard of care therapy will be mycophenolate mofetil (MMF) and initial optional treatment with IV methylprednisolone, followed by a tapering course of oral corticosteroids.
Patients are required to have a diagnosis of LN according to established diagnostic criteria and clinical and biopsy features suggestive of active nephritis.
Patients will be randomized in a 2:1 ratio to receive either zetomipzomib (30 mg or 60 mg) or placebo administered as a subcutaneous injection once weekly for 52 weeks, followed by a 4-week safety follow-up period. Efficacy will be assessed by measuring the level of proteinuria (as measured by urine protein to creatinine ratio [UPCR]) and estimated glomerular filtration rate (eGFR) as compared to current standard of care treatment. Safety will also be assessed throughout the study to ensure an acceptable safety profile.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Current or medical history of:
Has received dialysis within the 52 weeks prior to Screening
Positive test at Screening for HIV, hepatitis B/C
Known intolerance to MMF or equivalent and corticosteroids
Primary purpose
Allocation
Interventional model
Masking
279 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Kezar Life Sciences, Inc
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal